Standout Papers

Parotid-sparing intensity modulated versus conventional radiotherapy in hea... 2007 2026 2013 2019 1.2k
  1. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial (2011)
    Christopher M. Nutting, James P. Morden et al. The Lancet Oncology
  2. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial (2007)
    David P. Dearnaley, Matthew R. Sydes et al. The Lancet Oncology
  3. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial (2014)
    David P. Dearnaley, Gordana Jovic et al. The Lancet Oncology

Immediate Impact

64 standout
Sub-graph 1 of 17

Citing Papers

Prostate Cancer
2025 Standout
Radiotherapy toxicities: mechanisms, management, and future directions
2025 Standout
4 intermediate papers

Works of Christopher Scrase being referenced

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial
2011 Standout
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
2007 Standout

Author Peers

Author Last Decade Papers Cites
Christopher Scrase 2240 1553 797 1013 38 3.2k
Adam Raben 2973 1447 1056 1113 78 4.5k
Abrahim Al‐Mamgani 1560 1232 781 1112 86 2.8k
Carlos A. Perez 2380 1153 1704 1020 92 5.2k
Jan J. Battermann 1513 1039 450 331 58 2.3k
Wilma D. Heemsbergen 3950 3163 684 480 113 5.0k
Elizabeth Miles 1196 1126 713 1150 65 2.3k
W. Hinkelbein 2162 668 559 341 104 3.0k
W. Van den Bogaert 913 626 668 819 68 2.4k
N. Di Muzio 2211 1485 420 267 137 3.2k
Peter H. Blitzer 1163 546 1190 389 42 2.6k

All Works

Loading papers...

Rankless by CCL
2026